TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells

Wang, Xinfeng; Wang, Jingjing; Liu, Hong; Xu, Ruirong; Run-sheng, Ding; Jiang, Shenhua; Wang, Xudong; Huang, Hongming

doi:10.1007/s12032-015-0671-2

Cited by 5 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The underlying mechanism was subsequently explored. It is found that TRAF6 is highly expressed in myeloma cells and known to regulate the downstream NF-κB signaling pathways and participates in the proliferation and apoptosis of myeloma cells [26]. NF-κB is a pivotal regulator of the immune system and is involved in a variety of neoplastic diseases, which is known to be involved in IL-17A stimulation [27].…”

Section: Discussionmentioning

confidence: 99%

IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression

Wang

et al. 2019

Translational Oncology

Self Cite

View full text Add to dashboard Cite

PURPOSE: Elevated IL-17 produced by T h 17 cells was reported to promote myeloma cell growth and inhibit immune function in multiple myeloma (MM). IL-17A was also reported to promote MM growth through IL-17 receptors and enhance adhesion to bone marrow stromal cells (BMSCs). Spleen tyrosine kinase (Syk) influences MM cell survival and migration. Herein we aimed to investigate whether Syk was involved in the regulative role of IL-17A in the viability of MM cells. METHODS: Cell viability was determined using CCK8 assay. The production of cytokine including IL-17A was evaluated with ELISA. Western blotting assay was used to determine protein expression levels of Syk and nuclear factor κB (NF-κB) related molecules. mRNA expression level of RORγt was detected with reverse transcription quantitative polymerase chain reaction. RESULTS: IL-17Awas highly expressed in MM patients and was able to induce MM cell viability. Following analysis indicated that the effects of IL-17A were mediated by Syk/ nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. Immunoprecipitation also indicated that Syk is involved in IL-17A–induced Act1-TRAF6 complex formation and TRAF6 polyubiquitination in MM cells. CONCLUSIONS: Taken together, our study indicated that IL-17A increases MM cell viability through activating NF-κB signal pathway via positively regulating Syk expression. Syk also participates in the formation of IL-17R-proximal signaling complex (IL-17R-Act1-TRAF6), which is essential for IL-17A–mediated NF-kB activation. These investigations highlight that inhibition of Syk may be a potential therapeutic option for neoplastic diseases such as MM.

show abstract

Section: Discussionmentioning

confidence: 99%

IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression

Wang

et al. 2019

Translational Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bortezomib may be of more interest among the various therapeutic options in patients with AHA in the course of MM. Bortezomib has a directly cytotoxic effect on neoplasmatic plasma cells through the inhibition of the proteasome/nuclear factor-kappa B (NF-B) axis which is essential for interaction with the myeloma environment [57,58]. Furthermore, bortezomib has been described as an ISS drug efficient in SLE [59] and myasthenia gravis [60].…”

Section: Inhibitor Eradicationmentioning

confidence: 99%